-

Abveris Named as One of the Best Places to Work

CANTON, Mass.--(BUSINESS WIRE)--The Business Intelligence Group today announced that it has awarded Abveris, a division of Twist Bioscience, a Best Places to Work 2022. The organization sought to identify companies that are actively working to improve their own performance through efforts to challenge employees in environments that make work fun and engaging.

“We are deeply honored to have received the Best Places to Work award for the second consecutive year,” commented Tracey Mullen, VP, General Manager of Abveris, a division of Twist Bioscience. “At the heart of our division is a diverse team of collectively driven antibody enthusiasts who are united under a shared passion for technological advancement and unbridled scientific curiosity. Our team is our greatest asset and key to our success, and this award is a testament to that.”

“Congratulations to Abveris for building a workplace focused on employee engagement and performance,” said Maria Jimenez, Chief Nominations Officer of Business Intelligence Group. “This clearly was the most challenging year for many companies, and it is clear this is a great place to work and employee feedback is not only listened to, but acted upon. Congratulations to the entire team.”

About Abveris

Abveris, a division of Twist Bioscience, provides premium in vivo antibody discovery services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.abveris.com.

About Business Intelligence Group

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry and business award programs, business executives—those with experience and knowledge—judge the programs. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

Contacts

Angela Bitting
Twist Bioscience
(925) 202-6211
abitting@twistbioscience.com

Maria Jimenez
Business Intelligence Group
+1 (909) 529-2737
jmaria@bintelligence.com

Abveris LogoAbveris Logo

Abveris

NASDAQ:TWST

Release Versions

Contacts

Angela Bitting
Twist Bioscience
(925) 202-6211
abitting@twistbioscience.com

Maria Jimenez
Business Intelligence Group
+1 (909) 529-2737
jmaria@bintelligence.com

More News From Abveris

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 in Boston, MA; fireside chat at 1:50 pm Eastern Time Barclays 28th Annual Global Health...

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), e...

Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist’s library preparation portfolio, wi...
Back to Newsroom